Table 1 General data of the patients at presentation
Patient No. | Gender | Age (years) | Serum autoantibodies | Organ involvement | BVAS | Titer of serum autoantibodies (lgT) | SNA binding IgG/IgG (%) |
|---|---|---|---|---|---|---|---|
1 | F | 73 | Anti-MPO+ | K | 10 | 3.20 | 7.80 |
2 | M | 68 | Anti-MPO+ | K | 12 | 3.81 | 8.60 |
3 | M | 62 | Anti-MPO+ | K | 14 | 2.60 | 6.76 |
4 | F | 15 | Anti-MPO+ | K | 12 | 3.81 | 10.20 |
5 | F | 62 | Anti-MPO+ | K | 16 | 3.51 | 7.75 |
6 | F | 77 | Anti-MPO+ | K, L | 19 | 3.2 | 12.00 |
7 | M | 53 | Anti-MPO+ | K, L | 20 | 3.81 | 12.0 |
8 | M | 72 | Anti-MPO+ | K, L | 18 | 4.11 | 13.3 |
9 | F | 62 | Anti-MPO+ | K, L, G, N | 22 | 3.81 | 13.1 |
10 | M | 14 | Anti-MPO+ | K | 11 | 4.11 | 9.11 |
11 | M | 68 | Anti-MPO+, anti-GBM+ | K, L | 13 | 2.60, 2.90* | 7.20 |
12 | F | 13 | Anti-MPO+, anti-GBM+ | K, L, G | 15 | 3.81, 2.60* | 11.60 |
13 | M | 68 | Anti-MPO+, anti-GBM+ | K, L, G, J | 20 | 2.60, 2.90* | 11.83 |
14 | M | 62 | Anti-MPO+, anti-GBM+ | K, L, ENT | 15 | 2.00, 3.20* | 7.22 |
15 | M | 58 | Anti-MPO+, anti-GBM+ | K, ENT | 17 | 2.90, 3.51* | 6.98 |
16 | M | 70 | Anti-MPO+, anti-GBM+ | K, J, ENT | 14 | 3.81, 2.90* | 6.34 |
17 | M | 19 | Anti-GBM+ | K, L | -- | 3.81 | 13.05 |
18 | M | 26 | Anti-GBM+ | K, L | -- | 3.51 | 6.68 |
19 | M | 24 | Anti-GBM+ | K, L | -- | 2.90 | 22.37 |
20 | M | 27 | Anti-GBM+ | K | -- | 3.20 | 8.20 |
21 | M | 17 | Anti-GBM+ | K | -- | 3.20 | 6.86 |
22 | M | 26 | Anti-GBM+ | K | -- | 2.90 | 12.44 |
23 | M | 72 | Anti-PR3+ | K, L, J, ENT | 18 | 2.00 | 18.68 |
24 | M | 67 | Anti-PR3+ | K | 9 | 2.00 | 4.00 |
25 | M | 68 | Anti-PR3+ | K, L, J, ENT | 21 | 2.60 | 6.30 |
26 | F | 21 | Anti-PR3+ | K, L, | 16 | 2.00 | 14.7 |
27 | M | 50 | Anti-PR3+ | K, ENT | 14 | 2.90 | 8.23 |